Trial reportMedicine2026
The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study.
Trial report in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTo investigate the efficacy and safety of methylene blue infiltrating injection (MBI) in alleviating postoperative pain following hemorrhoidectomy.
methodsIn a randomized clinical trial, 60 patients with mixed hemorrhoids undergoing Milligan-Morgan surgery were divided into 2 groups: a study group (n = 30) and a control group (n = 30). Upon surgical completion, patients in the study group received an intraoperative MBI to the surgical incisions. All patients, in both groups, then received the same standard postoperative on-demand intravenous lornoxicam protocol. The primary outcome was anal pain intensity assessed by the visual analog scale scores at 6, 24, 48, and 72 hours. Secondary outcomes included limb movement score, incision edema, duration of the first postoperative defecation, supplemental analgesic consumption, length of hospital stay, hospitalization costs, and serum levels of substance P, 5-hydroxytryptamine, and prostaglandin E2.
resultsNo significant differences were observed in baseline characteristics. The study group exhibited significantly lower visual analog scale scores at all time points (all P < .001) and required substantially less supplemental lornoxicam (22.67 ± 17.01 mg vs 56.80 ± 9.32 mg, P < .001). Patients in the study group also had better limb movement scores, less incision edema, a shorter duration of the first postoperative defecation, a reduced hospital stay, and lower medical costs (P < .01). Serum levels of substance P, 5-hydroxytryptamine, and prostaglandin E2 were significantly lower in the study group (all P < .05). No perianal cellulitis, skin necrosis, or thrombosis occurred in either group.
conclusionMBI provides effective and safe analgesia after Milligan-Morgan surgery, significantly reducing pain, analgesic consumption, hospital stay, and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.